Saturday 17 October 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 2,778.6%, EPS grew 90.9% and free cash flow fell 59.8%, each against the same quarter a year earlier.
4.86
0.53
−9.83%
Follow ALGS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| (113.59%) | (121.86%) | (196.92%) | (141.82%) | ||
| (75.57%) | (83.92%) | (30.50%) | (87.25%) | ||
ROIC |
(3,379.28%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(216.31%) | (238.33%) | (38.10%) | (103.57%) | |
Average Days of Receivables |
321.69 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(9.06) | (8.19) | (8.39) | (7.67) | |
Free Cash Flow |
(94.52) | (85.18) | (82.94) | (79.53) | |
Capital Expenditures |
(0.35) | (0.46) | (0.44) | (0.37) | |
| Other line items | |||||
Cash ROIC |
(151.71%) | (98.06%) | (63.07%) | (46.47%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.04 | 0.01 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
280.40% | 1,664.25% | 3,177.17% | 2,586.73% | |
Selling, General and Administrative Expense of Revenue |
70.23% | 469.14% | 947.76% | 791.19% | |
Share Based Compensation of Revenue |
17.78% | 114.75% | 230.74% | 199.96% | |
Operating CF/Net income |
1.24 | 0.94 | 3.41 | 0.92 | |
Depreciation/Fixed assets |
(0.42) | (0.87) | (0.67) | (0.48) | |
Capex/Depreciation |
0.63 | 0.33 | 0.35 | 0.38 | |
Revenue per Share |
3.02 | 0.45 | 0.22 | 0.26 | |
Operating CF per Share |
(9.03) | (8.14) | (8.35) | (7.63) | |
Capex per Share |
(0.03) | (0.04) | (0.04) | (0.04) | |
Capex to Sales |
0.01 | 0.10 | 0.20 | 0.14 |
Columns are period end dates